According to a new report published by Allied Market Research, titled, “Immune Checkpoint Inhibitors Market: Global Opportunity Analysis and Industry Forecast, 2021-2030” The global immune checkpoint inhibitors market was valued at $29,803.71 million in 2020, and is projected to reach $1,40,890.10 million by 2030, registering a CAGR of 16.8% from 2021 to 2030.

Checkpoint inhibitor is a type of drug used in immunotherapy, which helps block the proteins present on tumor cells as they affect functioning of the immune system. Immune checkpoint inhibitor drugs block different checkpoint proteins including CTLA-4 (cytotoxic T lymphocyte associated protein 4), PD-1 (programmed cell death protein 1), and PD-L1 (programmed death ligand 1). Immune checkpoint inhibitor targets checkpoint proteins and assists the immune system to recognize and attack cancer cells. 

𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐏𝐃𝐅 𝐁𝐨𝐮𝐜𝐡𝐞𝐫:

The immune checkpoint inhibitors market is segmented on the basis of type, application, and region. On the basis of, the market is classified as CTLA-4 inhibitor, PD-1 inhibitor, PD-L1 inhibitor, and others. According application, it is categorized into lung cancer, bladder cancer, melanoma, Hodgkin lymphoma, and others. By region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞 𝐈𝐧𝐪𝐮𝐢𝐫𝐲:

𝐂𝐎𝐕𝐈𝐃-𝟏𝟗 𝐒𝐜𝐞𝐧𝐚𝐫𝐢𝐨 𝐀𝐧𝐚𝐥𝐲𝐬𝐢𝐬:

The overall impact of COVID-19 remains negative on the immune checkpoint inhibitor market, owing to decline in number of cancer patients visits in hospitals and clinics for immune checkpoint inhibitor therapy (ICI) which lead to decline in the demand of Immune checkpoint inhibitors products. For instance, according to NCBI in 2020 around 50% of patient decrease is reported for cancer care in U.S. and overall cancer therapies are declined by 50% during COVID-19. Furthermore, WHO issued guidelines regarding the nonessential planned therapies such as for cancer and procedures based on the need of critical situations? The guidelines suggest to provide emergency services to patients who require urgent attention and postpone the therapies and surgery if not urgent, which lead to decline in the demand for immune check point products in the market. 

𝐊𝐞𝐲 𝐁𝐞𝐧𝐞𝐟𝐢𝐭𝐬:

  • This report provides a detailed quantitative analysis of the current Immune checkpoint inhibitors market trends and forecast estimations from 2020 to 2030, which assists to identify the prevailing market opportunities. 
  • An in-depth market analysis includes analysis of various regions, which is anticipated to provide a detailed understanding of the current trends to enable stakeholders formulate region-specific plans.
  • A comprehensive analysis of factors that drive and restrain the growth of the global is provided.
  • The projections in this report are made by analyzing the current trends and future market potential from 2021 to 2030, in terms of value.
  • An extensive analysis of various regions provides insights that are expected to allow companies to strategically plan their business moves.
  • Key market players within the Immune checkpoint inhibitors market are profiled in this report and their strategies are analyzed thoroughly, which helps in understanding competitive outlook of the Immune checkpoint inhibitors market.

𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐂𝐮𝐬𝐭𝐨𝐦𝐢𝐳𝐚𝐭𝐢𝐨𝐧:

Comprehensive competitive analysis and profiles of major market players such as AstraZeneca PLC, Bristol-Myers Squibb Company, Eli Lilly and Company (ARMO Biosciences.) GlaxoSmithKline Plc, F. Hoffmann-La Roche Ltd. (Genentech, Inc.,), Sanofi, Merck & Co., Inc., Merck KGaA (EMD Serono, Inc.), and BeiGene Ltd, Shanghai Jhunsi Biosciences Ltd. 

𝐎𝐭𝐡𝐞𝐫 𝐓𝐫𝐞𝐧𝐝𝐢𝐧𝐠 𝐑𝐞𝐩𝐨𝐫𝐭𝐬:

Surgical Robotic System Market:

Healthcare Interoperability Solutions Market:

Surgical Drains Market

𝐀𝐛𝐨𝐮𝐭 𝐔𝐬

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP, based in Portland, Oregon. AMR provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

AMR introduces its online premium subscription-based library Avenue, designed specifically to offer cost-effective, one-stop solution for enterprises, investors, and universities. With Avenue, subscribers can avail an entire repository of reports on more than 2,000 niche industries and more than 12,000 company profiles. Moreover, users can get an online access to quantitative and qualitative data in PDF and Excel formats along with analyst support, customization, and updated versions of reports.

Contact Us:

David Correa
5933 NE Win Sivers Drive
205, Portland, OR 97220
United States
Toll Free: 1-800-792-5285
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1-855-550-5975

Leave a comment

Your email address will not be published. Required fields are marked *